Key statistics
On Monday, Sandoz Group AG (D8Y:BRN) closed at 67.64, -6.34% below its 52-week high of 72.22, set on Feb 25, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 67.32 |
|---|---|
| High | 69.28 |
| Low | 67.32 |
| Bid | 67.52 |
| Offer | 67.67 |
| Previous close | 67.88 |
| Average volume | 3.24k |
|---|---|
| Shares outstanding | 440.00m |
| Free float | 419.60m |
| P/E (TTM) | 42.03 |
| Market cap | 29.73bn CHF |
| EPS (TTM) | 1.61 CHF |
| Annual div (ADY) | 0.80 CHF |
|---|---|
| Annual div yield (ADY) | 1.18% |
| Div ex-date | Apr 17 2025 |
| Div pay-date | Apr 23 2025 |
| Next div ex-date | Apr 13 2026 |
| Next div pay-date | Apr 15 2026 |
Data delayed at least 15 minutes, as of Mar 02 2026.
More ▼
Announcements
- Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
- Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
- Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
- Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
- Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
- Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
- Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
- Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
- Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
- [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
More ▼
